The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma

Christian Theodotou, Ashish H. Shah, Seth Hayes, Amade Bregy, Jeremiah N. Johnson, Mohammad A. Aziz-Sultan, Ricardo J Komotar

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Glioblastoma multiforme (GBM) is an aggressive tumor with poor survival outcomes and limited treatment options. We conducted a literature review to compare the survival outcomes of intra-arterial (IA) and intravenous (IV) chemotherapy delivery for GBM. Nine studies of IA chemotherapy infusion with 301 total patients met our criteria for inclusion and three studies contained IV treatment groups for comparison (n = 230 for IA, n = 71 for IV). The studies were grouped by either using newly diagnosed or recurrent GBM patients. In the newly diagnosed group, IV chemotherapy produced a statistically higher median overall survival (MOS; 16.3 months) compared with IA treatment (14.02 months). However, the total number of adverse events in IA chemotherapy was 1.08 per patient whereas for IV it was higher at 1.54 events per patient. Our recurrent GBM group includes only patients treated with IA chemotherapy which resulted in an average MOS of 10.84 months. This group had 2.7 adverse events per patient but no IV group is available for comparison. Historically, the survival of patients with recurrent GBM ranges from 3 to 9 months (Gil-Gil et al. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013;7:123-35). For this reason, we believe IA chemotherapy to be a viable methodology in recurrent GBM patients to prolong survival at the risk of procedure-related complications and in newly diagnosed patients with the benefit of decreased complications.

Original languageEnglish
Pages (from-to)438-446
Number of pages9
JournalBritish Journal of Neurosurgery
Volume28
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Adjuvant Chemotherapy
Glioblastoma
Drug Therapy
Survival
Therapeutics
Intra Arterial Infusions

Keywords

  • Chemotherapy
  • Complications
  • Glioblastoma
  • Intra-arterial
  • Systematic review

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma. / Theodotou, Christian; Shah, Ashish H.; Hayes, Seth; Bregy, Amade; Johnson, Jeremiah N.; Aziz-Sultan, Mohammad A.; Komotar, Ricardo J.

In: British Journal of Neurosurgery, Vol. 28, No. 4, 01.01.2014, p. 438-446.

Research output: Contribution to journalArticle

Theodotou, C, Shah, AH, Hayes, S, Bregy, A, Johnson, JN, Aziz-Sultan, MA & Komotar, RJ 2014, 'The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma', British Journal of Neurosurgery, vol. 28, no. 4, pp. 438-446. https://doi.org/10.3109/02688697.2013.877122
Theodotou C, Shah AH, Hayes S, Bregy A, Johnson JN, Aziz-Sultan MA et al. The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma. British Journal of Neurosurgery. 2014 Jan 1;28(4):438-446. https://doi.org/10.3109/02688697.2013.877122
Theodotou, Christian ; Shah, Ashish H. ; Hayes, Seth ; Bregy, Amade ; Johnson, Jeremiah N. ; Aziz-Sultan, Mohammad A. ; Komotar, Ricardo J. / The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma. In: British Journal of Neurosurgery. 2014 ; Vol. 28, No. 4. pp. 438-446.
@article{26f983cb5dd94972a861702d7f372fde,
title = "The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma",
abstract = "Glioblastoma multiforme (GBM) is an aggressive tumor with poor survival outcomes and limited treatment options. We conducted a literature review to compare the survival outcomes of intra-arterial (IA) and intravenous (IV) chemotherapy delivery for GBM. Nine studies of IA chemotherapy infusion with 301 total patients met our criteria for inclusion and three studies contained IV treatment groups for comparison (n = 230 for IA, n = 71 for IV). The studies were grouped by either using newly diagnosed or recurrent GBM patients. In the newly diagnosed group, IV chemotherapy produced a statistically higher median overall survival (MOS; 16.3 months) compared with IA treatment (14.02 months). However, the total number of adverse events in IA chemotherapy was 1.08 per patient whereas for IV it was higher at 1.54 events per patient. Our recurrent GBM group includes only patients treated with IA chemotherapy which resulted in an average MOS of 10.84 months. This group had 2.7 adverse events per patient but no IV group is available for comparison. Historically, the survival of patients with recurrent GBM ranges from 3 to 9 months (Gil-Gil et al. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013;7:123-35). For this reason, we believe IA chemotherapy to be a viable methodology in recurrent GBM patients to prolong survival at the risk of procedure-related complications and in newly diagnosed patients with the benefit of decreased complications.",
keywords = "Chemotherapy, Complications, Glioblastoma, Intra-arterial, Systematic review",
author = "Christian Theodotou and Shah, {Ashish H.} and Seth Hayes and Amade Bregy and Johnson, {Jeremiah N.} and Aziz-Sultan, {Mohammad A.} and Komotar, {Ricardo J}",
year = "2014",
month = "1",
day = "1",
doi = "10.3109/02688697.2013.877122",
language = "English",
volume = "28",
pages = "438--446",
journal = "British Journal of Neurosurgery",
issn = "0268-8697",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma

AU - Theodotou, Christian

AU - Shah, Ashish H.

AU - Hayes, Seth

AU - Bregy, Amade

AU - Johnson, Jeremiah N.

AU - Aziz-Sultan, Mohammad A.

AU - Komotar, Ricardo J

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Glioblastoma multiforme (GBM) is an aggressive tumor with poor survival outcomes and limited treatment options. We conducted a literature review to compare the survival outcomes of intra-arterial (IA) and intravenous (IV) chemotherapy delivery for GBM. Nine studies of IA chemotherapy infusion with 301 total patients met our criteria for inclusion and three studies contained IV treatment groups for comparison (n = 230 for IA, n = 71 for IV). The studies were grouped by either using newly diagnosed or recurrent GBM patients. In the newly diagnosed group, IV chemotherapy produced a statistically higher median overall survival (MOS; 16.3 months) compared with IA treatment (14.02 months). However, the total number of adverse events in IA chemotherapy was 1.08 per patient whereas for IV it was higher at 1.54 events per patient. Our recurrent GBM group includes only patients treated with IA chemotherapy which resulted in an average MOS of 10.84 months. This group had 2.7 adverse events per patient but no IV group is available for comparison. Historically, the survival of patients with recurrent GBM ranges from 3 to 9 months (Gil-Gil et al. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013;7:123-35). For this reason, we believe IA chemotherapy to be a viable methodology in recurrent GBM patients to prolong survival at the risk of procedure-related complications and in newly diagnosed patients with the benefit of decreased complications.

AB - Glioblastoma multiforme (GBM) is an aggressive tumor with poor survival outcomes and limited treatment options. We conducted a literature review to compare the survival outcomes of intra-arterial (IA) and intravenous (IV) chemotherapy delivery for GBM. Nine studies of IA chemotherapy infusion with 301 total patients met our criteria for inclusion and three studies contained IV treatment groups for comparison (n = 230 for IA, n = 71 for IV). The studies were grouped by either using newly diagnosed or recurrent GBM patients. In the newly diagnosed group, IV chemotherapy produced a statistically higher median overall survival (MOS; 16.3 months) compared with IA treatment (14.02 months). However, the total number of adverse events in IA chemotherapy was 1.08 per patient whereas for IV it was higher at 1.54 events per patient. Our recurrent GBM group includes only patients treated with IA chemotherapy which resulted in an average MOS of 10.84 months. This group had 2.7 adverse events per patient but no IV group is available for comparison. Historically, the survival of patients with recurrent GBM ranges from 3 to 9 months (Gil-Gil et al. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol 2013;7:123-35). For this reason, we believe IA chemotherapy to be a viable methodology in recurrent GBM patients to prolong survival at the risk of procedure-related complications and in newly diagnosed patients with the benefit of decreased complications.

KW - Chemotherapy

KW - Complications

KW - Glioblastoma

KW - Intra-arterial

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=84905496128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905496128&partnerID=8YFLogxK

U2 - 10.3109/02688697.2013.877122

DO - 10.3109/02688697.2013.877122

M3 - Article

C2 - 24432794

AN - SCOPUS:84905496128

VL - 28

SP - 438

EP - 446

JO - British Journal of Neurosurgery

JF - British Journal of Neurosurgery

SN - 0268-8697

IS - 4

ER -